[Long term treatment of advanced vinblastine-resistant lymphogranulomatosis with ibenzmethyzin (Natulan)].
D000284:Administration, Oral; D000293:Adolescent; D000328:Adult; D000368:Aged; D000469:Alkaline Phosphatase / Q000097:blood; D000510:Alpha-Globulins / Q000032:analysis; D000577:Amides / Q000008:administration & dosage* / Q000009:adverse effects; D000970:Antineoplastic Agents / Q000008:administration & dosage* / Q000009:adverse effects; D001799:Blood Sedimentation; D004361:Drug Tolerance; D005260:Female; D006689:Hodgkin Disease / Q000097:blood / Q000145:classification / Q000000981:diagnostic imaging / Q000188:drug therapy* / Q000201:enzymology; D006801:Humans; D006834:Hydrazines / Q000008:administration & dosage* / Q000009:adverse effects; D008134:Long-Term Care; D008220:Lymphography; D008297:Male; D008875:Middle Aged; D012075:Remission, Spontaneous; D013997:Time Factors; D014747:Vinblastine / Q000627:therapeutic use
D000510:Alpha-Globulins; D000577:Amides; D000970:Antineoplastic Agents; D006834:Hydrazines; D014747:Vinblastine; D000469:Alkaline Phosphatase
Langzeitbehandlung der fortgeschrittenen vinglastinresistenten Lymphogranulomatose mit Ibenzmethyzin (Natulan)